Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Multiple Myeloma × Tablets × Clear all

Phase

Status

Withdrawn 1 Recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 2 Prostatic Neoplasms 1 Myofibroma 1 Multiple Myeloma 1 Lymphoma, Follicular 1 Leukemia, Myeloid, Acute 1 Leiomyoma 1 Insulin Resistance 1 Endometriosis 1 Dementia 1 Cognitive Dysfunction 1 Alzheimer Disease 1

Interventions

Dexamethasone 36 Lenalidomide 17 Calcium Dobesilate 15 Bortezomib 15 Melphalan 14 pomalidomide 8 Cyclophosphamide 8 elotuzumab 7 carfilzomib 6 pembrolizumab 5 ixazomib 5 daratumumab 5 Filgrastim 5 selinexor 4 fludarabine phosphate 4 fludarabine 4 dexamethasone acetate 4 Thalidomide 4 dexamethasone 21-phosphate 3 Vorinostat 3 Tacrolimus 3 Nivolumab 3 Magnetic Resonance Spectroscopy 3 Leukapheresis 3 Granulocyte Colony-Stimulating Factor 3 venetoclax 2 plerixafor 2 liposomal doxorubicin 2 auricularum 2 Zoledronic Acid 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02756663 2016-11-08

PANORAMA-5

Novartis

Phase 2 Withdrawn

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡